Research programme: protein serine threonine kinase inhibitors - MyrexisAlternative Names: MPI-0485520; MPI-485520
Latest Information Update: 26 Nov 2012
At a glance
- Originator Myriad Pharmaceuticals
- Developer Myrexis
- Class Small molecules
- Mechanism of Action I-kappa B kinase inhibitors; Protein-serine-threonine kinase inhibitors
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- Available For Licensing Yes - Cancer; Inflammation; Rheumatoid arthritis
Highest Development Phases
- Suspended Cancer; Diabetes mellitus; Inflammation; Obesity; Rheumatoid arthritis; Systemic lupus erythematosus